|
US20090263900A1
(en)
|
2008-04-14 |
2009-10-22 |
Sangamo Biosciences, Inc. |
Linear donor constructs for targeted integration
|
|
WO2009054985A1
(en)
|
2007-10-25 |
2009-04-30 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted integration
|
|
JP5756016B2
(ja)
*
|
2008-10-29 |
2015-07-29 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
グルタミンシンセターゼ遺伝子の発現を不活性化する方法及び組成物
|
|
ES2627552T3
(es)
|
2008-12-04 |
2017-07-28 |
Sigma Aldrich Company |
Edición de genoma en ratas usando nucleasas con dedos de cinc
|
|
KR101683928B1
(ko)
*
|
2008-12-17 |
2016-12-07 |
다우 아그로사이언시즈 엘엘씨 |
Ｚｐ１５ 유전자 자리 내로의 표적화 통합
|
|
JP6215533B2
(ja)
*
|
2009-04-09 |
2017-10-18 |
サンガモ セラピューティクス， インコーポレイテッド |
幹細胞への標的組込み
|
|
US8772008B2
(en)
*
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
|
WO2011007193A1
(en)
*
|
2009-07-17 |
2011-01-20 |
Cellectis |
Viral vectors encoding a dna repair matrix and containing a virion-associated site specific meganuclease for gene targeting
|
|
JP5940977B2
(ja)
|
2009-08-11 |
2016-06-29 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
標的改変によるホモ接合生物
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
WO2011090804A1
(en)
*
|
2010-01-22 |
2011-07-28 |
Dow Agrosciences Llc |
Targeted genomic alteration
|
|
EP2660318A1
(en)
|
2010-02-09 |
2013-11-06 |
Sangamo BioSciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
SG185367A1
(en)
|
2010-04-26 |
2012-12-28 |
Sangamo Biosciences Inc |
Genome editing of a rosa locus using zinc-finger nucleases
|
|
WO2011139349A1
(en)
|
2010-05-03 |
2011-11-10 |
Sangamo Biosciences, Inc. |
Compositions for linking zinc finger modules
|
|
JP6208580B2
(ja)
|
2010-05-17 |
2017-10-04 |
サンガモ セラピューティクス， インコーポレイテッド |
新規のｄｎａ結合タンパク質及びその使用
|
|
JP6050230B2
(ja)
*
|
2010-07-21 |
2016-12-21 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
Ｈｌａ遺伝子座の修飾のための方法及び組成物
|
|
EP2622090B1
(en)
|
2010-09-27 |
2019-06-19 |
Sangamo Therapeutics, Inc. |
Compositions for inhibiting viral entry into cells
|
|
RU2608643C2
(ru)
|
2010-10-12 |
2017-01-23 |
Дзе Чилдрен`З Хоспитал Оф Филадельфия |
Способы и композиции для лечения гемофилии в
|
|
EP2737063B1
(en)
|
2011-07-25 |
2016-06-01 |
Sangamo BioSciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
CA2848417C
(en)
|
2011-09-21 |
2023-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of transgene expression
|
|
CA3099582A1
(en)
|
2011-10-27 |
2013-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the hprt locus
|
|
WO2013158309A2
(en)
*
|
2012-04-18 |
2013-10-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-disruptive gene targeting
|
|
CN104364380B
(zh)
|
2012-04-25 |
2018-10-09 |
瑞泽恩制药公司 |
核酸酶介导的使用大靶向载体的靶向
|
|
WO2013169802A1
(en)
|
2012-05-07 |
2013-11-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
|
ES2613691T3
(es)
|
2012-07-11 |
2017-05-25 |
Sangamo Biosciences, Inc. |
Métodos y composiciones para el tratamiento de enfermedades por almacenamiento lisosomal
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
CA2878037C
(en)
|
2012-07-11 |
2021-08-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for delivery of biologics
|
|
AU2013308770B2
(en)
|
2012-08-29 |
2019-01-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
EP3763810A3
(en)
|
2012-10-10 |
2021-07-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
WO2014081855A1
(en)
*
|
2012-11-20 |
2014-05-30 |
Universite De Montreal |
Methods and compositions for muscular dystrophies
|
|
JP2016500254A
(ja)
|
2012-12-05 |
2016-01-12 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
代謝疾患の調節のための方法および組成物
|
|
BR102013032200A2
(pt)
|
2012-12-13 |
2015-11-24 |
Dow Agrosciences Llc |
direcionamento preciso de um gene para um locus específico em milho
|
|
EP2958996B1
(en)
|
2013-02-25 |
2019-10-16 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
US9937207B2
(en)
|
2013-03-21 |
2018-04-10 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell receptor genes using talens
|
|
MX369747B
(es)
|
2013-04-16 |
2019-11-20 |
Regeneron Pharma |
Modificación dirigida del genoma de rata.
|
|
AU2014262867B2
(en)
*
|
2013-05-10 |
2019-12-05 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
HK1223401A1
(zh)
|
2013-05-15 |
2017-07-28 |
桑格摩生物科学股份有限公司 |
用於治疗遗传病状的方法和组合物
|
|
EP3591045B1
(en)
|
2013-08-28 |
2024-07-17 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
US10117899B2
(en)
|
2013-10-17 |
2018-11-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
WO2015057980A1
(en)
|
2013-10-17 |
2015-04-23 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
US10369201B2
(en)
|
2013-11-11 |
2019-08-06 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating Huntington's disease
|
|
HRP20211706T1
(hr)
|
2013-11-13 |
2022-02-04 |
The Children's Medical Center Corporation |
Nukleazom posredovana regulacija ekspresije gena
|
|
CA2931848A1
(en)
|
2013-12-09 |
2015-06-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for genome engineering
|
|
RU2685914C1
(ru)
|
2013-12-11 |
2019-04-23 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
|
LT3102673T
(lt)
|
2014-02-03 |
2020-08-25 |
Sangamo Therapeutics, Inc. |
Beta talasemijos gydymo būdai ir kompozicijos
|
|
KR20150096064A
(ko)
*
|
2014-02-14 |
2015-08-24 |
서울대학교산학협력단 |
Ｍｄｃｋ ⅱ 세포의 크로모좀에서 ａａｖｓ1 위치를 인식하고 이곳에 외래 유전자를 도입하여 안정하게 발현시키는 방법
|
|
EP3110454B1
(en)
|
2014-02-24 |
2020-11-18 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
AU2015231353B2
(en)
|
2014-03-18 |
2020-11-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
|
KR102736149B1
(ko)
|
2014-03-21 |
2024-11-28 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
뉴클레아제 없는 게놈 편집
|
|
WO2015164748A1
(en)
|
2014-04-24 |
2015-10-29 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (tale) proteins
|
|
US20170037431A1
(en)
*
|
2014-05-01 |
2017-02-09 |
University Of Washington |
In vivo Gene Engineering with Adenoviral Vectors
|
|
GB201407852D0
(en)
|
2014-05-02 |
2014-06-18 |
Iontas Ltd |
Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
|
|
AU2015255877B2
(en)
|
2014-05-08 |
2020-03-26 |
Chdi Foundation, Inc. |
Methods and compositions for treating huntington's disease
|
|
CA2947622A1
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Genome editing methods and compositions for prevention or treatment of a disease
|
|
US9970001B2
(en)
|
2014-06-05 |
2018-05-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease design
|
|
HUE049776T2
(hu)
|
2014-06-06 |
2020-10-28 |
Regeneron Pharma |
Módszerek és készítmények egy célzott lókusz módosítására
|
|
WO2015200805A2
(en)
|
2014-06-26 |
2015-12-30 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modifications and methods of use
|
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
|
US9816074B2
(en)
|
2014-07-25 |
2017-11-14 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
|
KR20170054445A
(ko)
|
2014-09-16 |
2017-05-17 |
상가모 테라퓨틱스, 인코포레이티드 |
뉴클레아제-매개된 게놈 엔지니어링 및 조혈 줄기세포에서의 교정을 위한 방법 및 조성물
|
|
PT3207124T
(pt)
|
2014-10-15 |
2019-08-27 |
Regeneron Pharma |
Métodos e composições para a produção ou conservação de células pluripotentes
|
|
RU2734770C2
(ru)
|
2014-11-21 |
2020-10-23 |
Регенерон Фармасьютикалз, Инк. |
Способы и композиции для нацеленной генетической модификации с использованием парных гидовых рнк
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
RU2707137C2
(ru)
|
2014-12-19 |
2019-11-22 |
Регенерон Фармасьютикалз, Инк. |
Способы и композиции для нацеленной генетической модификации посредством одноэтапного множественного нацеливания
|
|
US20180002379A1
(en)
|
2015-01-21 |
2018-01-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
|
US20180022781A1
(en)
|
2015-02-13 |
2018-01-25 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
MX382223B
(es)
|
2015-05-12 |
2025-03-13 |
Sangamo Therapeutics Inc |
Regulacion de expresion genica mediada por nucleasa.
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
CN108024544B
(zh)
|
2015-07-13 |
2022-04-29 |
桑格摩生物治疗股份有限公司 |
用于核酸酶介导的基因组工程化的递送方法及组合物
|
|
WO2017029833A1
(ja)
*
|
2015-08-20 |
2017-02-23 |
大学共同利用機関法人情報・システム研究機構 |
動物細胞ゲノム部位特異的外来ｄｎａ挿入方法及び前記挿入方法を用いて得られる細胞
|
|
PT3352776T
(pt)
|
2015-09-23 |
2025-06-27 |
Sangamo Therapeutics Inc |
Repressores de htt e utilizações dos mesmos
|
|
AU2016343887B2
(en)
|
2015-10-28 |
2023-04-06 |
Sangamo Therapeutics, Inc. |
Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
|
|
JP6976249B2
(ja)
|
2015-11-23 |
2021-12-08 |
サンガモ セラピューティクス， インコーポレイテッド |
免疫を工学操作するための方法および組成物
|
|
WO2017106537A2
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Biosciences, Inc. |
Targeted disruption of the mhc cell receptor
|
|
WO2017106528A2
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Biosciences, Inc. |
Targeted disruption of the t cell receptor
|
|
EP3402533B1
(en)
|
2016-01-15 |
2021-08-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
EP3769775A3
(en)
|
2016-02-02 |
2021-03-17 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
CN106148286B
(zh)
*
|
2016-06-29 |
2019-10-29 |
牛刚 |
一种用于检测热原的细胞模型的构建方法和细胞模型及热原检测试剂盒
|
|
WO2018039448A1
(en)
|
2016-08-24 |
2018-03-01 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
|
HRP20212025T1
(hr)
|
2016-08-24 |
2022-04-01 |
Sangamo Therapeutics, Inc. |
Regulacija ekspresije gena pomoću projektiranih nukleaza
|
|
EP3509645A4
(en)
|
2016-09-07 |
2020-06-17 |
Sangamo Therapeutics, Inc. |
MODULATION OF LIVER GENES
|
|
MX2019004487A
(es)
|
2016-10-20 |
2020-02-07 |
Sangamo Therapeutics Inc |
Metodos y composiciones para el tratamiento de la enfermedad de fabry.
|
|
CA3041668A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
EP3580341A4
(en)
*
|
2017-02-09 |
2020-11-04 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and compositions and methods thereof
|
|
CN106978438B
(zh)
*
|
2017-02-27 |
2020-08-28 |
北京大北农生物技术有限公司 |
提高同源重组效率的方法
|
|
CA3061612A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
RU2019139045A
(ru)
|
2017-05-03 |
2021-06-03 |
Сангамо Терапьютикс, Инк. |
Способы и композиции для модификации гена регулятора трансмембранной проводимости при кистозном фиброзе (cftr)
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
RU2019143568A
(ru)
|
2017-07-31 |
2021-09-02 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для оценки crispr/cas-индуцированной рекомбинации с экзогенной донорной нуклеиновой кислотой in vivo
|
|
KR20200033259A
(ko)
*
|
2017-07-31 |
2020-03-27 |
리제너론 파마슈티칼스 인코포레이티드 |
생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물
|
|
AU2018309716B2
(en)
|
2017-07-31 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Cas-transgenic mouse embryonic stem cells and mice and uses thereof
|
|
AU2018364660B2
(en)
|
2017-11-09 |
2022-05-19 |
Sangamo Therapeutics, Inc. |
Genetic modification of cytokine inducible SH2-containing protein (CISH) gene
|
|
BR112020015488A2
(pt)
|
2018-02-08 |
2020-12-08 |
Sangamo Therapeutics, Inc. |
Nucleases alvo-específicas modificadas
|
|
EP3752601A4
(en)
|
2018-02-15 |
2022-03-23 |
Memorial Sloan-Kettering Cancer Center |
FOXP3-TARGETING AGENT COMPOSITIONS AND METHODS OF USE FOR ADOPTIVE CELL THERAPY
|
|
WO2019183123A1
(en)
|
2018-03-19 |
2019-09-26 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
|
JP7589047B2
(ja)
|
2018-04-05 |
2024-11-25 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現する細胞の作製方法および関連組成物
|
|
WO2019195491A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
WO2019204457A1
(en)
|
2018-04-18 |
2019-10-24 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (htt)
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
CA3109592A1
(en)
|
2018-08-23 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
|
EP3849565A4
(en)
|
2018-09-12 |
2022-12-28 |
Fred Hutchinson Cancer Research Center |
REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
|
|
EP3853244A4
(en)
|
2018-09-18 |
2022-09-14 |
Sangamo Therapeutics, Inc. |
PROGRAMMED CELL DEATH 1 (PD1) SPECIFIC NUCLEASES
|
|
IL322436A
(en)
|
2018-09-21 |
2025-09-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
WO2020069029A1
(en)
|
2018-09-26 |
2020-04-02 |
Emendobio Inc. |
Novel crispr nucleases
|
|
EP4667576A2
(en)
|
2018-10-18 |
2025-12-24 |
Intellia Therapeutics, Inc. |
Nucleic acid constructs and methods of use
|
|
CN113260701A
(zh)
|
2018-10-18 |
2021-08-13 |
英特利亚治疗股份有限公司 |
用于表达因子ix的组合物和方法
|
|
US12410402B2
(en)
|
2018-11-21 |
2025-09-09 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (NK) cell subset and related compositions and methods
|
|
EP3886869A4
(en)
|
2018-11-28 |
2022-07-06 |
Forty Seven, Inc. |
GENETICALLY MODIFIED ABLATION-RESISTANT HSPCS
|
|
WO2020146805A1
(en)
|
2019-01-11 |
2020-07-16 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
WO2020163379A1
(en)
|
2019-02-05 |
2020-08-13 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
|
US20220154157A1
(en)
|
2019-02-06 |
2022-05-19 |
Emendobio Inc. |
New engineered high fidelity cas9
|
|
KR20250148676A
(ko)
|
2019-04-03 |
2025-10-14 |
리제너론 파마슈티칼스 인코포레이티드 |
세이프 하버 좌위 내로의 항체 코딩 서열의 삽입을 위한 방법 및 조성물
|
|
MX2021013223A
(es)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
|
|
CN114025788A
(zh)
|
2019-05-01 |
2022-02-08 |
朱诺治疗学股份有限公司 |
从经修饰的tgfbr2基因座表达重组受体的细胞、相关多核苷酸和方法
|
|
KR20220038362A
(ko)
|
2019-07-02 |
2022-03-28 |
프레드 헛친슨 켄서 리서치 센터 |
재조합 ad35 벡터 및 관련 유전자 요법 개선
|
|
WO2021072115A1
(en)
|
2019-10-08 |
2021-04-15 |
Regents Of The University Of Minnesota |
Crispr-mediated human genome editing with vectors
|
|
EP4054651A1
(en)
|
2019-11-08 |
2022-09-14 |
Regeneron Pharmaceuticals, Inc. |
Crispr and aav strategies for x-linked juvenile retinoschisis therapy
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
|
EP4153741A1
(en)
|
2020-05-21 |
2023-03-29 |
Oxford Genetics Limited |
Hdr enhancers
|
|
GB202007578D0
(en)
|
2020-05-21 |
2020-07-08 |
Univ Oxford Innovation Ltd |
Hdr enhancers
|
|
GB202007577D0
(en)
|
2020-05-21 |
2020-07-08 |
Oxford Genetics Ltd |
Hdr enhancers
|
|
WO2021234388A1
(en)
|
2020-05-21 |
2021-11-25 |
Oxford Genetics Limited |
Hdr enhancers
|
|
US20240216508A1
(en)
|
2020-06-26 |
2024-07-04 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
WO2022011099A1
(en)
|
2020-07-08 |
2022-01-13 |
Regents Of The University Of Minnesota |
Modified hexosaminidase and uses thereof
|
|
BR112023000327A2
(pt)
|
2020-07-16 |
2023-01-31 |
Acuitas Therapeutics Inc |
Lipídeos catiônicos para o uso em nanopartículas lipídicas
|
|
EP4240756A1
(en)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
EP4313122A1
(en)
|
2021-03-23 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US12305184B2
(en)
|
2021-09-03 |
2025-05-20 |
North Carolina State University |
Compositions and methods for conferring resistance to geminivirus
|
|
MX2024005124A
(es)
|
2021-10-27 |
2024-05-16 |
Regeneron Pharma |
Composiciones y metodos para expresar el factor ix para terapia para la hemofilia b.
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
AU2022408167A1
(en)
|
2021-12-08 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
|
KR20240123832A
(ko)
|
2021-12-16 |
2024-08-14 |
아퀴타스 테라퓨틱스 인크. |
지질 나노입자 제형에 사용하기 위한 지질
|
|
US20230338477A1
(en)
|
2022-02-02 |
2023-10-26 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
|
EP4475671A1
(en)
|
2022-02-07 |
2024-12-18 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
|
WO2023150393A2
(en)
|
2022-02-07 |
2023-08-10 |
Ensoma, Inc. |
Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
|
|
EP4522201A1
(en)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
|
US20250302994A1
(en)
|
2022-05-09 |
2025-10-02 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
|
KR20250054842A
(ko)
|
2022-07-29 |
2025-04-23 |
리제너론 파마슈티칼스 인코포레이티드 |
뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법
|
|
KR20250075694A
(ko)
|
2022-09-28 |
2025-05-28 |
리제너론 파마슈티칼스 인코포레이티드 |
세포 기반 요법을 강화하기 위한 항체 저항성 변형 수용체
|
|
CN120693347A
(zh)
|
2022-11-04 |
2025-09-23 |
瑞泽恩制药公司 |
钙电压门控通道辅助亚基γ1(CACNG1)结合蛋白和CACNG1介导的向骨骼肌的递送
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
CN121002052A
(zh)
|
2023-02-03 |
2025-11-21 |
C3S2 有限公司 |
用于非病毒生产工程化免疫细胞的方法
|
|
WO2024168265A1
(en)
|
2023-02-10 |
2024-08-15 |
Possible Medicines Llc |
Aav delivery of rna guided recombination system
|
|
WO2024168253A1
(en)
|
2023-02-10 |
2024-08-15 |
Possible Medicines Llc |
Delivery of an rna guided recombination system
|
|
WO2024196965A1
(en)
|
2023-03-23 |
2024-09-26 |
Carbon Biosciences, Inc. |
Parvovirus compositions and related methods for gene therapy
|
|
US12383615B2
(en)
|
2023-03-23 |
2025-08-12 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
|
|
WO2025029662A1
(en)
|
2023-07-28 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr: acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
AR133385A1
(es)
|
2023-07-28 |
2025-09-24 |
Regeneron Pharma |
Inserción anti-tfr:gaa y anti-cd63:gaa para el tratamiento de la enfermedad de pompe
|
|
WO2025029654A2
(en)
|
2023-07-28 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
|
|
WO2025049524A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Cxcr4 antibody-resistant modified receptors
|
|
WO2025132815A1
(en)
|
2023-12-20 |
2025-06-26 |
Novozymes A/S |
Novel cas nucleases and polynucleotides encoding the same
|
|
US20250276092A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|